Avid Bioservices Inc (CDMO)

[biopharm]

"Dr Bernhard Hampl with ties to Great Point Partners and Cambrex...the same Cambrex where Gregory Sargen was CEO with right hand man Dr Ron Carroll with BMS ties with Gerald Finken.... much more investigating should be done ..."

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133039636

I am expanding some puzzle pieces here and when all is finished completely, I think there will be more than enough coincidental (or not?!) ties which show the 3 candidates have some backgrounds where Peregrine shareholders should at minimum be concerned....and make sure requests go into Ronin Capital Management or ANY new names added to make sure PS Long-term potential is BUILT into any partnership (such as matching shares...etc) and make sure Goldman Sachs like Medarex deals could never take place as bidding should be open to all Big Pharma if that is what the new BOD decide, NOT leaving any loopholes for private take over or one party bidding etc..

Gregory Sargen was CEO of Cambrex and Dr Bernard Hampl in the mix (would it not be funny if this person was on candidate short list of RCM lol) and with knowing how important being funded is and the ties to Great Point Partners, I find it very interesting how GPP saved the day of CSM CEO Gerald Finken that spoiled the days of Peregrine. Again, start a rather big puzzle and you will see the ties that should make you ask the tough questions of how far would some go to control PS Targeting for as cheap as possible ??

Through the Cytovance acquisition, Hepalink USA Inc. and its parent company Shenzhen Hepalink Pharmaceutical Co., Ltd. add a leading biologics CDMO to its current U.S. operations. Cytovance manufactures protein and antibody drugs for biotechnology and pharmaceutical companies throughout the world.

"This transaction expands our ability to develop and grow both our domestic and international businesses and will accelerate our current expansion plans in our Oklahoma City facilities," said Mr. Darren Head, President and Chief Executive Officer of Cytovance. He added, "Great Point Partners has been an outstanding private equity partner that arranged debt financings enabling growth, helped us recruit senior executives, and that provided Dr. Bernhard Hampl, former CEO of Sandoz USA, from their CEO Advisory Board as Co-Chairman."

Noah Rhodes, a Principal at GPP and Board member of Cytovance, stated, "When we invested in Cytovance in 2011 it was a relatively unknown company that had all of the right ingredients to become an industry leading CDMO, and our equity investment and relationships with senior lenders enabled the company to execute on an accelerated growth strategy. Since our investment four years ago, Cytovance has grown its revenue at a compound annual growth rate of 45% and is now considered one of the preeminent biologics contract manufacturers in the world."

About Great Point Partners

Great Point Partners ("GPP"), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $400 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or http://www.gppfunds.com.

https://globenewswire.com/news-release/2015/10/07/774099/10151927/en/Great-Point-Partners-I-Portfolio-Company-Cytovance-Biologics-Is-Acquired-by-Hepalink-USA.html